Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease | ||
By: Nasdaq / GlobeNewswire - 18 Jun 2018 | Back to overview list |
|
First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer's Disease Research Unit and Yale PET Center Pittsburgh, June 18, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today announced that patient dosing has begun in the SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition) study of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. SPARC (COG0105) is a randomized, double-blind, placebo-controlled study designed to compare changes in synaptic density in 21 Alzheimer’s disease patients who will receive treatment with Elayta or placebo once daily for 24 weeks. Synaptic density will be determined at baseline and after 12 and 24 weeks of dosing using positron emission tomography (PET) imaging with a carbon-11-labeled radioligand tracer, UCB-J, that is selective for synaptic vesicle glycoprotein 2A (SV2A), a membrane protein expressed in the majority of synapses. Patients will be enrolled at the Yale Alzheimer's Disease Research Unit under the direction of co-investigators Christopher van Dyck, M.D. and Richard E. Carson, Ph.D. The SPARC study is funded by a $4.1 million grant from the National Institute on Aging of the NIH under award number RF1AG057553. “The link between synaptic density and cognitive function has been well characterized and is highly correlated with cognitive decline in Alzheimer’s disease. If synapse numbers stabilize or increase in these Alzheimer’s disease patients after Elayta treatment compared to placebo, the SPARC study could yield very important insights for the Alzheimer’s disease community,” said Dr. van Dyck, director of the Yale Alzheimer's Disease Research Unit, and a professor of psychiatry, neurology and neuroscience. “This is the first longitudinal study of the [11C]UCB-J imaging agent in patients with Alzheimer’s disease,” stated Dr. Carson, the director of the Yale PET Center and director of Yale graduate studies in biomedical engineering, and professor of radiology, biomedical imaging and biomedical engineering. He added, “Alzheimer’s disease patients experience a degeneration of synapses, caused in part by the binding of toxic A? oligomers (A?Os) to neuronal receptors. This methodology has the potential to quantify synaptic density in the brain and, as a result, to become an important tool in the development of new therapies for Alzheimer’s disease and other neurocognitive disorders.” “PET imaging of SV2A in SPARC has the potential to demonstrate Elayta’s synaptorestorative effect in patients with Alzheimer’s disease. Further, we expect that the increase in synaptic density will correlate with improved cognition and function among trial participants,” stated Cognition co-founder and Chief Science Officer Susan Catalano, Ph.D. “Elayta’s unique synaptorestorative mechanism of action indirectly destabilizes the A?O binding site, thereby displacing A?Os from synapses and clearing them out of the brain into the cerebrospinal fluid. We have shown in vitro that synaptic density returns to normal levels following treatment with Elayta and look forward with great anticipation to the results of the SPARC trial.” More information about SPARC is available at www.ClinicalTrials.gov. About Elayta (CT1812) About Cognition Therapeutics, Inc. Forward-Looking Statements CONTACT: Contact Information: Cognition Therapeutics, Inc. info@cogrx.com Aline Sherwood Scienta Communications asherwood@scientapr.com |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |